X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has achieved GMP (Good Manufacturing Practice) commercial readiness with its flagship product, XT-Thrive®.
XT-Thrive® enables non-toxic cryopreservation for life-saving regenerative medicines such as vaccines, cell lines for production, cell and gene therapies, and engineered tissues. The DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media is designed to significantly enhance the preservation of biological materials, offering unprecedented efficiency and reliability.
“This announcement marks a critical step forward in ensuring the highest quality and scalability of XT-Thrive® for widespread clinical and commercial applications,” said Mark Kline, co-founder and Chief Technology Officer at X-Therma. “This milestone not only opens new opportunities for advancing cryopreservation solutions that can save countless lives, but also marks the first time peptoids, an emerging class of biomimetic molecules, have been utilized at a market-ready scale.”
Also Read: Cellworks Group Inc. announced it has opened a new computational laboratory in Franklin, TN
“With GMP commercial readiness, XT-Thrive® will meet the stringent quality and regulatory standards required for clinical use, positioning X-Therma as a key player in the biopreservation market,” said Mike Osborne, SVP of Commercial, Regenerative Medicine at X-Therma. “This demonstrates our progression towards being able to meet increasing market demands and support large-scale clinical applications.”
SOURCE: PRNewswire